gp100 (209-217), G209-2M – 1 mg

Overview

The gp100 (209-217), G209-2M peptide is a critical tool in cancer research, specifically targeting melanoma. This peptide represents a vital epitope derived from the gp100 antigen, which plays an essential role in T-cell recognition. Designed for applications in immunology and oncology research, G209-2M enhances the recognition and affinity by modifying the second amino acid to methionine. As a result, this modification significantly boosts the peptide’s potential for T-cell activation, making it an invaluable asset for studies in therapeutic development and vaccine research.

Key Features

• Derived from the gp100 melanoma antigen, facilitating T-cell recognition.
• Contains a methionine modification at the second amino acid position, enhancing binding affinity to MHC HLA-A2.1.
• Available in a 1 mg vial, ideal for various research applications.
• Designed to support studies on T-cell activation and immune response against melanoma.
• Quality-assured for consistency and reliability in research settings.

Specifications

FAQ

What is the significance of the G209-2M modification?

The G209-2M modification enhances the binding affinity for the MHC HLA-A2.1 molecule, leading to improved T-cell activation against melanoma. This is crucial for developing effective immunotherapies.

How can I use this peptide in my research?

You can utilize the gp100 (209-217), G209-2M peptide for T-cell assays, vaccine development, and other immunological studies where T-cell recognition of melanoma antigens is relevant.

Where can I find more peptides for similar applications?

Explore our extensive catalog of peptides to discover additional options that suit your research needs. Products like PKG Substrate and Autocamtide-2 complement the gp100 peptide in various assays and applications.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled